clinical cancer research

期刊名称 clinical cancer research 

期刊缩写 CLIN CANCER RES   
学科分类 医学、生命科学 

出版周期 月刊   
审稿速度 2.07 个月 （平均） 

投稿命中率 27.22 % （均值)   
期刊主页 http://clincancerres.aacrjournals.org/   
ISSN 号 1078-0432   
IF 趋势    2005      2006      2007      2008       2009      2010      2011      2012    
              5.715      6.177     6.25       6.488       6.747    7.338      7.742     7.837   
被收录情况   1. Science Citation Index 
                    2. Science Citation Index Expanded 
                    3. Current Contents - Clinical Medicine 
                    4. BIOSIS Previews   
PubSci评语 一审40天左右，非常注重新意。难度与Cancer research 相当，但偏临床。建议实验与临床相结合，实验设计一定要合理且有新意。一般修回的话补实验是肯定的，如果以前有相关的实验基础可能中的机率更大点。   
期刊简介 美国癌症研究学会杂志。关注点在如下领域：靶向治疗的临床和转化研究、药物敏感性和耐药性的机制、遗传药理学和药物基因组学、个性化医学、生物信息学和生物统计学的新应用、免疫和临床免疫学、基因治疗、放射生物学和放射肿瘤学、人类肿瘤的大规模分子特征、诊断标志物、临床遗传学以及微小疾病的诊断方法。   
投稿注意事项 特别提醒：2013年开始，AACR引入了开放获取论文发表形式，以该方式发表的论文需要交纳3000美元，不必再支付版面费，但彩页费用仍要另计。不选择Open access形式发表的作者需要支付版面费，首页费用对于AACR会员是85美元，非会员95美元。首页以后，会员每页110美元，非会员每页120美元。
 
一般注意事项：
Editorial Policies     
General Publishing Policies     
 
Authorship  
   
Who should be listed as an author is determined by the authors or by policies at their institutions, or both. As a general guideline, persons listed as authors should have contributed substantially to 1) the conception and design of the study, acquisition of data, or analysis and interpretation of data; 2) drafting of the article or revising it for important content; and 3) final approval of the version to be published. The corresponding author is responsible for ensuring that all authors have agreed 1) to be authors and to be listed in the order specified by the submitting author; 2) to the manuscript's content; and 3) to its submission to the journal. If any changes to authorship are proposed after the manuscript is submitted (including the order of author listing), the corresponding author must provide the AACR Publications Department with signed documentation (Authorship Change Form) from each author on the manuscript, including those being added, removed, or rearranged in byline order, affirming that the authors all agree to the changes. AACR journals accept no responsibility for deciding matters of authorship.   
 
Author contributions  
   
Authors submitting to AACR journals will now be required to indicate the contribution(s) each has made to the manuscript at its revision stage. Potential contributions include:
Conception and design
Development of methodology
Acquisition of data
Analysis and interpretation of data
Writing, review and/or revision of the manuscript
Administrative, technical, or material support
Study supervision
Other   
 
Group authorship  
   
AACR publications follow the recommendations on group authorship presented in the Council of Science Editors (CSE) White Paper on Promoting Integrity in Scientific Journal Publications. The submitting author must identify any group named as an author as well as the named individuals from that group who accept responsibility for the article.
If all individuals belonging to the group take responsibility, then the group itself is an author and all members must be named and sign copyright release forms. In this case the group name should appear in the byline, and the names of all members should appear in a note. However, if the group is the only author, then at least one author must be identified by name who will be responsible for manuscript communications, and who will respond to inquiries about the published article. This author's name and contact information should be presented as the Corresponding Author in a note on the title page.
Byline examples:
The XYZ Group (the group is the only author)
Author1, Author2,  . . ., and the XYZ Group (the group is one of several authors)
If a subset of group members is taking responsibility for the article, then these individuals must be named and sign copyright release forms. In this case, the named members should appear in the byline along with the group name. Other members who are not authors may be listed in the Acknowledgments.
Byline examples:
Author1, Author2, and Author3 for the XYZ Group (the three authors are writing on behalf of the Group)
Author1, Author2, Author3; Author4 and Author5 for the XYZ Group; Author6, Author7. . .  (authors 4 and 5 are writing on behalf of the group; other authors are unaffiliated with the group)   
 
No prior or subsequent publication  
   
When a manuscript is submitted for consideration, the authors should confirm in writing that neither the submitted manuscript nor any similar manuscript, in whole or in part, other than an abstract, is under consideration, in press, or published elsewhere. The corresponding author is responsible for attesting to this on behalf of all authors via the online submission form.   
 
Conflict of interest  
   
AACR journal policy requires that authors and reviewers reveal to the Editors-in-Chief, Deputy Editors, Senior Editors, or Scientific Editors any relationships that they believe could be construed as resulting in an actual, potential, or perceived conflict of interest with regard to the manuscript submitted for review. All new and revised submissions to AACR journals must include such a statement. The authors are responsible for providing a detailed conflict of interest statement on the title page of their submission, even if there are no conflicts to disclose. To ensure that the editors and reviewers assigned have ready access, manuscripts will not enter the peer review process unless this statement is included. If the manuscript moves to the revision stage, each of the authors will be contacted and asked to complete an individual, electronic conflict-of-interest form. The existence of financial interests or other relationships of a commercial nature is not necessarily regarded as creating a conflict of interest. Rather, AACR journals' policy represents a recognition of the many factors that can influence judgments about research data and a desire to make as much information as possible available to those reviewing the data. If a potential conflict of interest is disclosed, notification concerning the relationship will be published along with the article.   
 
Embargo policy  
   
AACR's Communications Department periodically sends out news releases regarding upcoming articles of interest. Upon request from a reporter, AACR makes the full text of these articles available in advance of publication with the understanding that the embargo policy will be upheld. Embargo dates and times are stated on news releases sent by AACR.
If an author's institution is planning on promoting an accepted manuscript in one of the AACR journals, the author or institution should contact Jeremy Moore, Senior Manager for Science Communications, to determine embargo dates (Phone: (267) 646-0557; Fax: (215) 440-9410; Email: PublicationsPress@aacr.org) . Because AACR journals publish accepted manuscripts "OnlineFirst," usually within days of acceptance, it is important to contact the Communications Department to coordinate publicity efforts as soon as possible, preferably during the revision of the manuscript. The online article is considered the article of record, while the print issue follows as an archive.
Advanced release of material is intended for reporters only but may be shared with third parties such as coworkers at the author's institution or organization or experts in the field for the purposes of obtaining expert opinion and commentary. The reporter is responsible for communicating and obtaining an understanding from the third party that the embargo will be honored and the advance material will not be further distributed without permission from AACR's Communications Department.
Reporters should credit the appropriate AACR journal as the source of the information in any reports. Reproducing content from the advance material for inclusion in reports requires permission from AACR (see Copyright and Permissions).   
 
Confidentiality  
   
All reviewers and editors are required to adhere to ethical guidelines that mandate strict confidentiality concerning all aspects of the manuscripts and their content. Manuscripts submitted for consideration for publication are privileged communications, and the status of the manuscript and details regarding it are available only to AACR editorial staff, authors, and the editors and peer reviewers involved.
Submission of a manuscript implies acceptance by all authors of the strict policy of the AACR that under no circumstances will the identities of the editors, or information leading to the identities of the editors, be revealed.   
   
Availability and Deposit of Materials and Data     
 
General  
   
Materials, data, and protocols should be made available upon request and within a reasonable amount of time, with terms to be agreed upon by the party making the request and the authors. Restrictions on availability must be disclosed in the cover letter at the time of manuscript submission. Investigators must exercise great care to ensure that data and resources involving human subjects and materials derived from human subjects do not identify original donors or subjects either directly or through identifiers such as codes linked to the donors or subjects. These requirements are subject to amendment, as the need for disclosure is likely to change with evolving technologies. The publisher will contact the authors' institution(s) in cases where authors do not follow policy.   
 
Materials  
   
Unique materials, such as cells, plasmids, antibodies, or animal models, and protocols that were used in the research reported and which are not available from commercial suppliers must be made available either through the authors' laboratories or organizations or through an appropriate collection or repository. If they are not submitted to a repository, the materials should be made available as long as they are currently used in the researchers' laboratories and available to the researchers themselves. Materials that are difficult to obtain or cannot be easily propagated or synthesized are exempt from this requirement. Authors are not required to share materials when requests are for intended commercial use. The requesting party will be responsible for any reasonable associated cost.   
 
Data  
   
The publication of articles including new genes, proteins, genomics, SNPs, proteomics, or crystallographic structures is contingent upon deposition in a publicly accessible database, when available (see "Depositing Data in Public Databases"). Any corresponding accession numbers must be provided in the manuscript prior to acceptance for publication. Above-mentioned data for which a publicly available database does not exist must be made available for a period of 3 years, and requests for data are limited to those contained in the article. Also, authors may be required to make primary data available to editors or reviewers upon request. These reporting requirements extend to the sequences of oligonucleotides used in antisense strategies and RNA, the chemical structures of drugs and synthetic compounds that have not been previously published (see below), and the details of the synthesis or methods of production of the molecules and materials used in the experiments (if not commercially available). For previously reported structures and sequences, accurate references must be provided in the manuscript.   
 
Chemical structures and synthesis  
   
The exact chemical structures (and not simply the chemical names) of any unpublished synthetic, low-molecular-weight chemical compounds used as part of the described research (including clinical studies in humans) must be disclosed. For novel structures previously unreported, experimental details of the synthetic methodology should be included in the main body of the paper or in the Supplementary Data. Any references or patents cited that provide the synthesis of compounds should specifically identify the exact molecules that are studied in the paper; general references to patents are not sufficient.   
 
Depositing data in public databases  
   
The AACR requires that authors submitting manuscripts describing microarray data be prepared to supply peer reviewers with the data in a format that conforms to the Minimum Information About a Microarray Gene Experiment (MIAME) guidelines of the Microarray Gene Expression Data society (MGED). These guidelines include a checklist of information that should accompany each new microarray submission. Authors will also be required to deposit the data with either of 2 public repositories — GEO or Array Express — and to publish the accession numbers in the article.
Large data sets of peripheral significance to the main thesis of the investigation will not be published in the print journals but may be posted as a data supplement to the online version of the article. Supplementary Data must be submitted for review with the manuscript.
Authors of manuscripts with new nucleotide or amino acid sequences must deposit the sequence information with GenBank. Authors outside of the United States may elect to deposit sequence information in the European Molecular Biology Laboratory (EMBL) database or the DNA Databank of Japan.
Authors must submit the relevant accession numbers for deposited sequences with the manuscript and these will be published with the article. Whether a sequence is the one the author has deposited or if the author is simply referring to it in the text, the accession number or ID code should always be included in the text so that we can create a link to the appropriate database.
Examples:
  GenBank accession no. Y13182
  PDB ID code 2JVD   
 
Clinical trial registry  
   
In accordance with the guidelines published by the International Committee of Medical Journal Editors (ICMJE) and the changes to the policy published in an ICMJE editorial in June 2007, AACR journals require, as a condition of consideration for publication, that all clinical trials be registered in one of 5 ICMJE-approved public trial registries (www.ClinicalTrials.gov,www.actr.org.au, www.ISRCTN.org, www.umin.ac.jp/ctr/index/htm, or www.trialregister.nl). Trials must be registered at or before the onset of patient enrollment. In addition to accepting registration in any of the above 5 registries, and following the recommendation of ICMJE, AACR journals accept registration of clinical trials in any of the primary registers that participate in the World Health Organization (WHO) International Clinical Trial Registry Platform (ICTRP). Whether the trial is the subject of the paper or the author refers to other trials in the text, the registration number should always be included so that we can create a link to the trial's record in the appropriate database.
Examples:
  Trial registration ID: NCT00404079
  Trial registration ID: ISRCTN51857546
Registration only in a partner registry is insufficient. AACR journals have implemented the WHO definition of clinical trials for all trials that began enrollment on or after January 1, 2009. This definition states that a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes." For more information, see ICMJE Uniform Requirements for Manuscripts Submitted to Biomedical Journals.   
   
Data Presentation     
 
Electrophoretic gels and blots  
   
Authors are asked to include positive and negative controls, as well as molecular size markers, on each gel and blot and to provide a citation for previously characterized antibodies. For antibodies that are less well characterized in the system under study, we require a detailed characterization that demonstrates not only the specificity of the antibody but also the range of reactivity of the reagent in the assay, which will be published as Supplementary Data. Vertically sliced gels should be clearly separated, with no juxtaposed lanes, or a line can be included delineating the boundary between the lanes.
The display of cropped gels and blots in the main manuscript is encouraged if it improves the clarity and conciseness of the presentation. In such cases, the cropping must be mentioned in the figure legend. These uncropped images should be labeled as in the main text. The manuscript's figure legends should include the information noted below:
Cropped gels in the manuscript must retain important bands.
Cropped blots in the body of the manuscript should retain at least 6 bandwidths above and below the band.
High-contrast gels and blots are discouraged, as overexposure may mask additional bands. Authors should strive for exposures with gray backgrounds. High-contrast immunoblots should be surrounded by a black line to indicate the borders of the blot.
All image acquisition tools and image processing software must be described.   
 
Image acquisition and analysis  
   
It is the author's responsibility to exercise discretion during data acquisition, where misrepresentation must be avoided. Acquisition of images for comparative purposes must be standardized. Specimen areas should be selected that objectively represent the critical features being presented. Images should be captured in a noncompressing format such as TIFF or BMP. Authors should retain their unprocessed images and metadata files, as editors may request them to aid in manuscript evaluation. If unprocessed data are unavailable, manuscript evaluation may be delayed until the issue is resolved. Files that have been adjusted in any way should be saved separately from the originals, also in a noncompressed format. Compressed formats, such as JPG, should only be used for presentation of final figures, when requested, to keep file sizes small for electronic transmission.
Eight-bit monochrome or 24-bit RGB acquisition is acceptable for visual documentation, but the image should be captured at higher bit depths for fine analysis of intensity data. Only unprocessed original files should be used for analysis. If data are presented that include mathematical representations of pixel intensities and locations, the original unprocessed files must be provided for review.   
 
Image composites  
   
The grouping of images from different originals must be made explicit, both by the arrangement of the figure (i.e., adding dividing lines) and in the text of the figure legend. This arrangement also applies to multiple fields taken from the same image (such as individual lanes combined from a single electrophoresis gel) and separate images acquired with different conditions. If dividing lines are not included, they will be added by our production department, and this addition may result in publication delays.
Figures presenting merged color images from fluorescence originals must include the original single-channel images used to make the merged file. Original images captured as color files are acceptable, but grayscale images are preferred and should be laid out in sequence as part of the figure.
Multiple images may be combined into a single photomontage when the area of interest cannot be captured in a single image. In such a case, all images that make up the montage must be captured using a standardized method. Each smaller image must overlap its neighboring image by one quarter of the shared field in each direction. The outer boundary of the combined image must be clearly delineated with a line. Any post-processing must be done to the total combined montage.   
 
Image manipulation  
   
Publication in AACR journals is contingent on the minimal use of image adjustment, and the final image must remain representative. Adjustments of brightness, contrast, or color balance are acceptable only if they are applied to the whole image and as long as they do not obscure or eliminate any information present in the original, including backgrounds. Nonlinear manipulation, such as "gamma," should only be used to adjust the overall presentation of the image to assure that details are visible in the printed form. Alteration to specific features within the image is generally not acceptable. Subforms of an image should not be enhanced, obscured, moved or removed in relation to the larger image.
Nonlinear algorithms to enhance overall presentation, such as background subtraction, shading correction, sharpening, despeckling, and flattening, may be acceptable, but disclosure of adjustment must be included in the legend and the specific techniques must be described. Descriptions must include the original, unprocessed files for comparison.   
 
Microscopy  
   
Images made available to referees should be at least 300 dpi at the size in which they will be published. Adjustments should be applied to the entire image. Threshold manipulation, expansion or contraction of signal ranges and the altering of high signals should be avoided. "Pseudo-coloring" and nonlinear adjustment (e.g., "gamma changes") are only allowed if unavoidable and must be disclosed, as noted above. The following items should be included with the final revised version of the manuscript for publication:
Magnification scale bar for each image
In the Methods section — type of equipment (microscopes/objective lenses, cameras, detectors) used; acquisition software; and description of specialized techniques requiring large amounts of processing, such as confocal, deconvolution, 3D reconstructions, or surface and volume rendering   
 
Reporting on cell line use  
   
AACR strongly encourages the authentication of cell lines used in the research reported in its journals. If cell lines were used in the research, a statement addressing the following points must be included in the Materials and Methods section of the manuscript:
From where and when the cells were obtained
Whether the cell lines have been tested and authenticated
The method by which the cells were tested
How and when the cells were last tested
If cells were obtained directly from a cell bank that performs cell line characterizations and passaged in the user's laboratory for fewer than 6 months after receipt or resuscitation, reauthentication is not required. In these cases, the author should include the method of characterization used by the cell bank.
Resources for Authors regarding the cell line policy are available on our Author Services Center.   
 
Gene nomenclature  
   
In addition to the use of common names, authors are required to include the approved nomenclature at the first mention of any gene or protein described in their manuscript. All gene names, whether approved or common, must follow the correct format guidelines: italicized and all upper case when referring to human genes; and italicized and first letter upper case and the remainder lower case for mouse genes. (Complete instructions in nomenclature can be obtained from the organism-specific genome website; see below.) Protein names are the same as the gene symbol but not italicized and in all upper-case letters, regardless of organism. Inclusion of the approved nomenclature will minimize confusion and make it possible for the journal to provide links to the genome databases for the online version of the article. For example, the incorrect, but commonly used, names for Cdkn1a include Cip1, p21, Waf1, and Sdi1. In addition, p38 can ambiguously refer to several different genes, including Ahsa1, Grap2, Syp, and Aimp2, as well as Mapk14. Approved human gene symbols can be obtained from theHUGO Gene Nomenclature Committee website. Approved mouse nomenclature can be obtained from Mouse Genome Informatics. If no approved gene name exists, the authors must obtain an approved gene name from the appropriate committee or other resource through one of the links shown below:
Human:  http://www.genenames.org/about/contact-details
Mouse:  http://www.informatics.jax.org/mgihome/nomen/index.shtml
Rat:  http://rgd.mcw.edu/nomen/nomen.shtml   
 
Strain Information  
   
In experiments involving animal models, details concerning sex, age, weight, strain, substrain, and source must be delineated. The genetic crosses that were used to generate the experimental and control population must also be described. Strain information may be included in the Materials and Methods section (or Methods for Cancer Discovery) or in Supplementary Data. In descriptions of genetically engineered animals, the source and strain of the embryonic stem (ES) cell should be included, along with details on whether the animals have been maintained on the original background (isogenic with the ES cell genetic background), maintained on a mixed strain background, or made congenic onto another strain. In addition, the genotype of all experimental and control groups must be specified. Authors should follow the naming conventions outlined in a recent article (Montoliu L, Whitelaw CB. Transgenic Res 2011;20:435–40), which are summarized by the International Society for Transgenic Technologies.   
   
Submission Procedures     
 
Online submission to SmartSubmit  
    
All submissions must be made electronically through the AACR SmartSubmit online system. Before you submit a manuscript, be sure to read all the AACR Instructions for Authors as well as the specific instructions (links are at the top of this page) for the journal to which you are submitting. You will find complete details on how to submit a manuscript when you log on to SmartSubmit to create an author account. Each journal's SmartSubmit homepage is linked below:
 
Cancer Discovery Cancer Research   
Cancer Epidemiology, Biomarkers & Prevention Clinical Cancer Research   
Cancer Immunology Research Molecular Cancer Research   
Cancer Prevention Research Molecular Cancer Therapeutics 
When you submit your manuscript online, you will be asked to provide or select the following:
Title of the manuscript
Running title to appear at the top of each printed page
Full names and affiliations of all authors, complete with first and middle names or initials, and contact information (including email address) for each
The type of manuscript and an indication of whether or not it was invited
At least two keywords from the pull-down list of terms to classify your manuscript; in addition to the keyword selection, you may also provide your own keywords in the text boxes provided
Upload PDFs or other files for Supplementary Data (if applicable)
A cover letter to be uploaded along with your manuscript and graphics files; include a description of the novel and salient findings of the work, as well as pertinent information not covered elsewhere in the submission form
Abstract typed into the box provided; abstracts are often copied directly by secondary services, so they should recapitulate in abbreviated form the purpose of the study and the experimental technique, results, and interpretations of the data; they should include a synopsis of all pertinent data but not include references; abbreviations and acronyms should be avoided
Answers to questions about the manuscript, such as statement of authorship, and acceptance of color reproduction costs and page charges
When you have completed the submission form, you will be able to upload your cover letter, manuscript, and graphics files, and Supplementary Data (if applicable).    
 
Submission of files  
    
To expedite publication, accepted manuscripts are copyedited electronically. When submitting manuscripts, authors are strongly encouraged to upload original source files into the AACR SmartSubmit system. Uploading original source files will greatly facilitate publication of an accepted manuscript. The following are acceptable file formats:
Manuscript files: Word, WordPerfect, Encapsulated Postscript (EPS), Text, Postscript, Rich Text Format (RTF), or PDF (accepted for original submissions only; not for revisions)
Graphics files: TIFF, GIF, Postscript, PowerPoint (PPT), or EPS
Once you have successfully submitted your manuscript online, you will receive acknowledgment via email.    
 
Submitting revisions  
    
If you have been asked to revise your manuscript and you are ready to resubmit it, log on to the AACR SmartSubmit system and, on your author home page, click the "Revised Manuscript" link of the manuscript you wish to resubmit. You will be asked to review the information you originally submitted to confirm its accuracy. In your cover letter, please be sure to provide a point-by-point reply to the reviewers' comments as well as a listing of all the changes made, including any changes to authorship, noting the page numbers on which the individual changes appear.
When you have successfully resubmitted your manuscript, you will receive acknowledgment via email.
The revised version of your manuscript may undergo another review if the original submission required extensive changes or if the authors' responses to the criticisms entail rebuttal rather than revision. A decision as to whether or not the manuscript will be sent back out for review is made at the discretion of the Editors.    
 
Appeals for reconsideration  
    
Manuscripts that have been declined for publication will be reconsidered only at the discretion of the Editor(s). Authors who wish to request reconsideration of a previously rejected manuscript must do so in writing by sending correspondence that includes the manuscript ID number to the Editorial Office. Requests for reconsideration sent to a location other than the Editorial Office will not receive a reply. Please be advised that due to keen competition for journal space, only those manuscripts that have been judged to be of the highest priority can be accepted for publication. In your correspondence, please explain in detail the reasons why you feel the manuscript should be reconsidered. If it is determined that it should be reconsidered, you will be asked to submit it as a new manuscript. It will receive a new identification number and date of receipt and then undergo review as a new submission. Reconsidered manuscripts for Cancer Research will require payment of the standard submission fee. Please note that Clinical Cancer Research does not consider appeals.    
    
Format and Style     
Manuscripts should be written in clear, grammatical English, typed double-spaced, and all pages must be numbered. Manuscripts that are not in AACR style or that are not in good idiomatic English may be returned to the author without review. For the convenience of authors whose native language is not English, we have provided a list of editing and proofreading services for scientific manuscripts in our Author Services Center. Laboratory jargon as well as terminology and abbreviations not consistent with internationally accepted guidelines should be avoided.
The AACR journals generally conform to usage guidelines in Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers (Seventh Edition, 2006, published by the Council of Science Editors, Reston, VA). For general guidance on manuscript preparation, consult the documents issued by the International Committee of Medical Journal Editors.
Manuscripts should be arranged in the following order: title page, text and references, tables, legends for all tables and figures, figures. See below for full explanation of what is to be included in these sections. See also each journal's instructionsfor exceptions to these general instructions.
When submitting manuscripts that include Supplementary Data, please be sure to upload supplemental files separately, in the appropriate area of the submission form (See also the detailed policies on preparation of Supplementary Data). Please do not append supplemental files to the main manuscript file. Numbered and lettered sections in the text should be avoided. Each table and illustration must be cited in order in the text. Simple chemical formulas or mathematical equations should be presented in a form that allows their reproduction in single horizontal lines of type; more complicated mathematical formulas or chemical structures difficult to set in type should be provided for reproduction in the form of line drawings, glossy photographs, or digital files.    
 
Title page  
    
Title. Write a brief, informative title. Abbreviations should not be used in titles. It is important for literature retrieval to include in the title the key words that identify the nature of the subject matter, including, if applicable, the species on which the work is done.
Authors and affiliations. Authors are urged to include their full names, complete with first and middle names or initials. Academic degrees should not be included. The names and locations of institutions and the laboratories or names and locations of companies should be given for all authors. If several institutions are listed on a manuscript, it should be clearly indicated with which department and institution each author is affiliated by using superscript numbers that correspond to each author's affiliation.
Running title. A brief running title of about 60 characters should be provided. Choose the running title carefully as this version of your title will be used in electronic alerting services and some mobile device applications.
Keywords. Provide 5 keywords identifying the subject of your article.
Include the following notes on the title page (if applicable) in this order:
Financial support, including the source and number of grants, for each author
Full name, mailing address, phone and fax number, and email address of the corresponding author
Disclose any potential conflicts of interest; additional information is available at this link: Conflict of Interest Policy
Other notes about the manuscript as a whole, including the word count (excluding references), and thetotal number of figures and tables. Please note that if you exceed the limit given for the type of article (see specific instructions for each journal), your manuscript may be returned.     
 
Abstract  
    
The abstract should be concise, yet outline the content of the manuscript (see the specifications for each type of article for abstract length). Because these abstracts are used by secondary services (e.g., Medline, Chemical Abstracts, Web of Science, Scopus), they should recapitulate in abbreviated form the purpose of the study and the experimental technique, results, and data interpretations. Data such as the number of test subjects and controls, strains of animals or viruses, drug dosages and routes of administration, tumor yields and latent periods, length of observation period, and magnitude of activity should be included. Vague, general statements such as "The significance of the results is discussed," or "Some physical properties were studied," should be avoided. All important terms relevant to the content of the manuscript should be incorporated into the abstract to assist indexers and searchers. Abbreviations should be kept to an absolute minimum; however, if they are needed, they must be explained at first mention within the abstract so the abstract can be understood as an independent unit from the text. Do not cite references in the abstract.    
 
Introduction  
    
It is not necessary to cite all of the background literature in the Introduction. Brief reference to the most pertinent articles generally suffices to acquaint the reader with the findings of others in the field and with the problem or question that the investigation addresses.    
 
Materials and Methods  
    
Explanation of the experimental methods should be brief but adequate for repetition by qualified investigators. Procedures that have been described in previous publications should not be described in detail but merely cited with appropriate references. Only new and significant modifications of previously published procedures need complete exposition. The sources of special chemicals or preparations used should be provided. Any commercial products that are mentioned should include the name of the manufacturer, and ideally, catalog numbers.
AACR journals endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. In particular, manuscripts reporting human experimentation must include a statement that the human investigations were performed after approval by an institutional review board and in accordance with an assurance filed with and approved by the U.S. Department of Health and Human Services, where appropriate. Also, manuscripts reporting biomedical research involving human subjects must include a statement that informed consent was obtained from each subject or subject's guardian.
AACR journals are staunch supporters of the most humane treatment of animals in the conduct of scientific studies, and it is expected that investigators will adhere to widely accepted national standards such as the following:
The U.S. Public Health Service Policy on Humane Care and Use of Laboratory Animals, available from theOffice of Laboratory Animal Welfare, National Institutes of Health, Department of Health and Human Services, RKLI, Suite 360, MSC 7982, 6705 Rockledge Drive, Bethesda, MD 20892–7982.
The United Kingdom Coordinating Committee on Cancer Prevention Research's Guidelines for the Welfare of Animals in Experimental Neoplasia (published online 25 May 2010).
Only the results (particularly the photographic presentation of experimental data) in which proper attention has been given to ethical considerations toward animals will be published, and the AACR reserves the right to reject manuscripts that do not follow accepted standards.    
 
Results  
    
Include a concise summary of the data presented in tables and illustrations. Excessive elaboration of data already given in tables and illustrations should be avoided. With the exception of Cancer Discovery, the Results and Discussion sections should be combined if, by so doing, space is saved or the logical sequence of the material is improved.    
 
Discussion